Your browser doesn't support javascript.
loading
The Potential Revolution of Cancer Treatment with CRISPR Technology.
Stefanoudakis, Dimitrios; Kathuria-Prakash, Nikhita; Sun, Alexander W; Abel, Melissa; Drolen, Claire E; Ashbaugh, Camille; Zhang, Shiliang; Hui, Gavin; Tabatabaei, Yeganeh A; Zektser, Yuliya; Lopez, Lidia P; Pantuck, Allan; Drakaki, Alexandra.
Afiliación
  • Stefanoudakis D; School of Medicine, National & Kapodistrian University of Athens, 15772 Athens, Greece.
  • Kathuria-Prakash N; Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Sun AW; Department of Internal Medicine, Columbia University, New York, NY 10027, USA.
  • Abel M; Division of Hematology and Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.
  • Drolen CE; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Ashbaugh C; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Zhang S; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Hui G; Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Tabatabaei YA; Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Zektser Y; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Lopez LP; Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Pantuck A; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Drakaki A; Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Cancers (Basel) ; 15(6)2023 Mar 17.
Article en En | MEDLINE | ID: mdl-36980699
Immuno-oncology (IO) and targeted therapies, such as small molecule inhibitors, have changed the landscape of cancer treatment and prognosis; however, durable responses have been difficult to achieve due to tumor heterogeneity, development of drug resistance, and adverse effects that limit dosing and prolonged drug use. To improve upon the current medicinal armamentarium, there is an urgent need for new ways to understand, reverse, and treat carcinogenesis. Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) 9 is a powerful and efficient tool for genome editing that has shown significant promise for developing new therapeutics. While CRISPR/Cas9 has been successfully used for pre-clinical cancer research, its use in the clinical setting is still in an early stage of development. The purpose of this review is to describe the CRISPR technology and to provide an overview of its current applications and future potential as cancer therapies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Grecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Grecia